Varian to Acquire Boston Scientific’s Oncology Assets for $90M

 Varian to Acquire Boston Scientific’s Oncology Assets for $90M


  • Varian acquires the Boston Scientific drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products for the treatment of arteriovenous malformations and hypervascular tumors for $90M
  • The focus of the acquisition is to expand Varian’s interventional oncology portfolio and to get benefits from the acquired product’s regulatory clearances in 35+ countries globally
  • Varian plans to manufacture & distribute the products without acquiring Boston Scientific operations. The transaction is expected to close on Aug’2019

Click here to read full press release/ article | Ref: Varian | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post